Newly developed anti-angiogenic therapy in non-small cell lung cancer

Jingjing Qu; Yongchang Zhang; Xue Chen; Haiyan Yang; Chunhua Zhou; Nong Yang

doi:10.18632/oncotarget.23755

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Newly developed anti-angiogenic therapy in non-small cell lung cancer

Jingjing Qu, Yongchang Zhang, Xue Chen, Haiyan Yang, Chunhua Zhou and Nong Yang _

PDF | HTML | How to cite

Oncotarget. 2018; 9:10147-10163. https://doi.org/10.18632/oncotarget.23755

Metrics: PDF 2524 views | HTML 3131 views | ?

Abstract

Jingjing Qu1, Yongchang Zhang1, Xue Chen1, Haiyan Yang1, Chunhua Zhou1 and Nong Yang1

1Department of Lung Cancer and Gastrointestinal Oncology Medicine, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China

Correspondence to:

Nong Yang, email: [email protected]

Keywords: angiogenesis; combined with chemotherapy; tyrosine kinase inhibitor; immunotherapy; NSCLC

Received: August 13, 2017 Accepted: November 16, 2017 Published: December 26, 2017

ABSTRACT

Angiogenesis and its role in the growth and development of non-small cell lung cancer (NSCLC) metastases has become an increasing clinical problem. Vascular endothelial growth factor (VEGF) plays a key role in advanced NSCLC. To some extent, anti-angiogenic therapies acquired some efficacy in combination with chemotherapy, target therapy and immunotherapy. However, the reliable clinical benefit obtained with these drugs is still questionable and often quantitatively limited. In this review, the authors highlight the data obtained from first-line, second-line, epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) target therapy and immunotherapy in NSCLC patients who are treated with anti-angiogenic molecules in advanced NSCLC. The purpose of this study is to help us truly understand how to best use angiogenesis therapy in advanced NSCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23755

Publication Alerts

Post-Publication Promotion

Reviews:

Newly developed anti-angiogenic therapy in non-small cell lung cancer

Abstract